N4 Pharma (N4P) Competitors GBX 0.50 +0.04 (+8.70%) As of 12:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitors N4P vs. RGT, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, APH, and AGYShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Argent BioPharma Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Alliance Pharma Allergy Therapeutics Argent BioPharma (LON:RGT) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Does the media refer more to RGT or N4P? In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Argent BioPharma Neutral N4 Pharma Neutral Does the MarketBeat Community prefer RGT or N4P? N4 Pharma received 103 more outperform votes than Argent BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformArgent BioPharmaN/AN/AN4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Which has higher earnings & valuation, RGT or N4P? N4 Pharma has higher revenue and earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24N/AN4 Pharma£8.84K243.55-£1.63M-£0.35-1.44 Is RGT or N4P more profitable? Argent BioPharma has a net margin of -1,960.39% compared to N4 Pharma's net margin of -18,399.86%. Argent BioPharma's return on equity of 420.08% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharma-1,960.39% 420.08% -108.57% N4 Pharma -18,399.86%-90.68%-56.00% Which has more risk & volatility, RGT or N4P? Argent BioPharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Do insiders & institutionals hold more shares of RGT or N4P? 1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArgent BioPharma beats N4 Pharma on 6 of the 11 factors compared between the two stocks. Remove Ads Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.15M£2.26B£5.70B£2.59BDividend Yield3.12%2.92%4.41%4.98%P/E Ratio-1.444.3024.15155.62Price / Sales243.55659.20394.56313,884.32Price / Cash2.2510.2538.1627.90Price / Book1.126.917.104.58Net Income-£1.63M£20.70B£3.19B£5.76B7 Day Performance2.04%2.24%1.79%-0.01%1 Month Performance-10.23%-1.31%2.32%3.32%1 Year Performance-23.08%95.17%14.79%126.26% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.50+8.7%N/A-34.3%£2.15M£8,841.37-1.445Gap UpRGTArgent BioPharmaN/AN/AN/AN/A£8.31MN/A-0.65N/AGap DownHigh Trading VolumeHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A-0.27N/AHLNHaleon0.444 of 5 starsGBX 388.50-0.2%GBX 420+8.1%+24.0%£35.06B£11.07B32.6725,408High Trading VolumeBXPBeximco PharmaceuticalsN/AGBX 37-2.6%N/A-2.2%£25.22B£7.08T3.975,500News CoverageGap DownHIKHikma Pharmaceuticals2.9404 of 5 starsGBX 2,016-2.7%GBX 2,436.67+20.9%+3.8%£5.59B£3.74B19.789,100HCMHUTCHMEDN/AGBX 240-0.8%N/A-7.7%£2.61B£771.01M-61.251,760News CoverageGap DownHigh Trading VolumeINDVIndivior2.0299 of 5 starsGBX 736.50-1.7%GBX 1,650+124.0%-52.8%£1.15B£1.40B-610.661,000Gap UpAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma1.7796 of 5 starsGBX 64.20+0.3%GBX 6,250+9,635.2%+70.7%£347.61M£183.50M-10.3591,000AGYAllergy TherapeuticsN/AGBX 6.80flatN/A+146.3%£334.23M£72.18M-6.55612 Remove Ads Related Companies and Tools Related Companies Argent BioPharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Alliance Pharma Alternatives Allergy Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 3/21/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free N4P Stock Alerts